291 – 300 of 304
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2000
-
Mark
No association between the alpha2-macroglobulin (A2M) deletion and Alzheimer's disease, and no change in A2M mRNA, protein, or protein expression
(
- Contribution to journal › Article
- 1999
-
Mark
Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment
(
- Contribution to journal › Article
-
Mark
Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample
(
- Contribution to journal › Article
- 1998
-
Mark
Decreased monoamine metabolites in frontotemporal dementia and Alzheimer's disease
(
- Contribution to journal › Article
- 1997
-
Mark
Somatostatin and neuropeptide Y in cerebrospinal fluid: correlations with severity of disease and clinical signs in Alzheimer's disease and frontotemporal dementia
(
- Contribution to journal › Article
-
Mark
The apolipoprotein E epsilon4 allele frequency is normal in fronto-temporal dementia, but correlates with age at onset of disease
(
- Contribution to journal › Article
- 1996
-
Mark
Correlation between clinical characteristics and cerebrospinal fluid neuropeptide Y levels in dementia of the Alzheimer type and frontotemporal dementia
(
- Contribution to journal › Article
- 1995
-
Mark
Long-term effects of tacrine on regional cerebral blood flow changes in Alzheimer's disease
(
- Contribution to journal › Article
- 1994
-
Mark
Tacrine treatment modifies cerebrospinal fluid neuropeptide levels in Alzheimer's disease
(
- Contribution to journal › Article
- 1993
-
Mark
Neuropeptides in cerebrospinal fluid of patients with Alzheimer's disease and dementia with frontotemporal lobe degeneration
(
- Contribution to journal › Article